Bankrupt Drug Sale Ties Most Value to Milestones
Connecticut healthcare operators weighing similar deals should treat contingent milestone payments as uncertain value.
Updated on Nov. 2, 2026 in Healthcare
Live Poll
Do you trust large companies to treat workers fairly when they go bankrupt?
BioXcel Therapeutics completed a $57.5 million sale of its main drug assets to Teva Pharmaceuticals on October 26, after filing for Chapter 11 bankruptcy protection in August. The company is preparing to wind down and liquidate, which affects its remaining workforce and the market for the anti-agitation drug Igalmi.
Why it matters
The bankruptcy followed years of losses, multiple rounds of layoffs, and efforts to expand the market for Igalmi, a sequence that shows how difficult it can be for a small drug developer to sustain operations without a commercial breakthrough. For Connecticut's healthcare and life-sciences operators, the case is a reminder that upfront sale value can be only part of a deal, with the rest contingent on regulatory milestones.
The $57.5 million upfront price is the figure directly tied to the sale, with up to $67.5 million more contingent on FDA approval of Igalmi for at-home use and $10 million payments at each of two annual sales thresholds ($250 million and $500 million). The company reported 29 employees at the end of 2025, and Mehta's board pay is set at $5,000 a month beginning November 1. Whether the FDA will grant at-home approval, and whether sales ever reach the milestone levels, has not been established.
The players
BioXcel Therapeutics
A New Haven-based drug developer whose business centered on commercializing Igalmi, now winding down and liquidating after its Chapter 11 filing.
Teva Pharmaceuticals
A large generic and specialty pharmaceutical manufacturer that acquires and commercializes branded and generic medicines across global markets.
U.S. Bankruptcy Court in Delaware
The federal court that oversees Chapter 11 cases and approved the asset sale, setting the terms under which creditors and buyers resolve a distressed company's assets.
The details
Teva had agreed to buy the assets when BioXcel entered bankruptcy, subject to competing offers and court approval, and the Delaware bankruptcy court approved the sale on October 21. The package includes rights to Igalmi, related research and intellectual property, and a pending federal application for at-home use. Sale proceeds were used to repay loans that financed the bankruptcy operations, and four top executives, including the CEO and CFO, were terminated effective October 31. Samir Saleem was appointed president and secretary and will serve as principal executive officer during the wind-down.
Timeline
August 2026: BioXcel filed for Chapter 11 bankruptcy protection.
October 21, 2026: The Delaware bankruptcy court approved the sale.
October 26, 2026: The sale to Teva closed.
October 31, 2026: Four top executives were terminated.
Market Landscape
The deal follows a familiar pattern in which small drug developers that fail to scale a commercial product transfer it to larger pharmaceutical buyers through court-supervised bankruptcy sales. Structuring part of the price as milestone payments tied to FDA approval and sales thresholds is a common way to bridge valuation gaps between buyer and seller.
Operators in Connecticut's life-sciences and healthcare sector should treat contingent milestone payments as uncertain value when evaluating similar deals or partnerships. Vendors and service providers tied to BioXcel's wind-down should confirm their claims and contract status with the bankruptcy process.
The takeaway
Treat milestone-based sale terms as contingent value rather than guaranteed proceeds when assessing a distressed asset sale. Business owners with receivables or contracts involving BioXcel should track the bankruptcy docket and the company's name change to BX Liquidation Inc. to stay current on claims.
Further reading
For broader context on how drug developers navigate funding and regulatory pressure, see the Healthcare section.
Source note: This article includes information reported by Hartford Business Journal.
Live Poll
Do you trust large companies to treat workers fairly when they go bankrupt?
